Sanctuary Advisors LLC Boosts Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Sanctuary Advisors LLC grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.4% during the third quarter, Holdings Channel reports. The firm owned 3,288 shares of the company’s stock after acquiring an additional 558 shares during the period. Sanctuary Advisors LLC’s holdings in IDEXX Laboratories were worth $1,661,000 as of its most recent filing with the SEC.

Other institutional investors have also recently modified their holdings of the company. FSA Wealth Management LLC acquired a new position in IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Ridgewood Investments LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter worth $27,000. E Fund Management Hong Kong Co. Ltd. increased its stake in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC raised its holdings in shares of IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the last quarter. Finally, Strategic Investment Solutions Inc. IL acquired a new position in IDEXX Laboratories during the second quarter valued at $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on IDXX. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays reduced their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $539.63.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the sale, the director now owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Stock Down 0.4 %

Shares of NASDAQ IDXX opened at $409.03 on Friday. The firm has a market cap of $33.49 billion, a price-to-earnings ratio of 39.44, a price-to-earnings-growth ratio of 3.99 and a beta of 1.37. The company’s 50-day simple moving average is $435.18 and its 200-day simple moving average is $469.56. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same period in the previous year, the firm posted $2.53 EPS. IDEXX Laboratories’s revenue was up 6.6% compared to the same quarter last year. Equities analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.